- Home
- EVOK vs LIXT Comparison
EVOK vs LIXT Comparison
Compare EVOK & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- LIXT
- Stock Information
- Founded
- EVOK 2007
- LIXT 2005
- Country
- EVOK United States
- LIXT United States
- Employees
- EVOK N/A
- LIXT N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- LIXT Health Care
- Exchange
- EVOK Nasdaq
- LIXT Nasdaq
- Market Cap
- EVOK 4.2M
- LIXT 4.1M
- IPO Year
- EVOK 2013
- LIXT N/A
- Fundamental
- Price
- EVOK $2.95
- LIXT $1.33
- Analyst Decision
- EVOK
- LIXT
- Analyst Count
- EVOK 0
- LIXT 0
- Target Price
- EVOK N/A
- LIXT N/A
- AVG Volume (30 Days)
- EVOK 14.3K
- LIXT 22.1K
- Earning Date
- EVOK 05-13-2025
- LIXT 05-12-2025
- Dividend Yield
- EVOK N/A
- LIXT N/A
- EPS Growth
- EVOK N/A
- LIXT N/A
- EPS
- EVOK N/A
- LIXT N/A
- Revenue
- EVOK $11,594,083.00
- LIXT N/A
- Revenue This Year
- EVOK $57.82
- LIXT N/A
- Revenue Next Year
- EVOK $59.12
- LIXT N/A
- P/E Ratio
- EVOK N/A
- LIXT N/A
- Revenue Growth
- EVOK 89.89
- LIXT N/A
- 52 Week Low
- EVOK $1.94
- LIXT $1.02
- 52 Week High
- EVOK $12.32
- LIXT $3.50
- Technical
- Relative Strength Index (RSI)
- EVOK 38.86
- LIXT 50.90
- Support Level
- EVOK $3.33
- LIXT $1.16
- Resistance Level
- EVOK $3.66
- LIXT $1.49
- Average True Range (ATR)
- EVOK 0.29
- LIXT 0.11
- MACD
- EVOK -0.06
- LIXT 0.00
- Stochastic Oscillator
- EVOK 2.99
- LIXT 51.45
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.